Breast Cancer Connect
  • Saved
Participation in community-based healthcare interventions and non-communicable diseases early detection of general population in Indonesia

Participation in community-based healthcare interventions and non-communicable diseases early detection of general population in Indonesia

Source : https://www.sciencedirect.com/science/article/pii/S2352827322002154?via=ihub

CBHIs are a distinct mode of healthcare delivery and are regarded as a critical component of healthcare task-sharing in LMICs. * CBHIs have the potential to address LMICs' health system...


Conclusion and Recommendation: CBHIs may benefit NCDs early detection for the general population in Indonesia. Policymakers and health practitioners need to design CBHIs programs that are attractive to the population, especially men and younger people.

  • Saved
Anti-breast cancer drugs targeting cell-surface glucose-regulated protein 78: a drug repositioning in silico study - PubMed

Anti-breast cancer drugs targeting cell-surface glucose-regulated protein 78: a drug repositioning in silico study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36129131/

Breast cancer (BC) is prevalent worldwide and is a leading cause of death among women. However, cell-surface glucose-regulated protein 78 (cs-GRP78) is overexpressed in several types of cancer and during...


Conclusion: These findings demonstrate the efficacy of abemaciclib, ribociclib, and tunicamycin in binding to the nucleotide-binding domain of the GRP78, paving the way for elucidating the mode of interactions between these drugs and cancer (and other stressed) cells that overexpress GRP78.

  • Saved
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study - PubMed

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36135204/

1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7 AY, UK. 2 Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, 91190 Gif-sur-Yvette, France. 3 Department of...


Conclusions: Our study strongly supports the notion that CDK4/6 inhibitors induce tumour immune modulation. N/L ratio and platelet levels decreased due to treatment. Future studies should test whether patients would benefit from immunomodulators in association with CDK4/6 agents in a larger clinical trial. Moreover, the CDK4/6-induced immune...

  • Saved
Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors

Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors

Source : https://ascopubs.org/doi/full/10.1200/OP.22.00219

One quarter of all practicing physicians in the United States and over one third of all US hematologists and oncologists are international medical graduates (IMGs). IMGs are defined as physicians...


Relevance: One quarter of all practicing physicians in the United States and over one third of all US hematologists and oncologists are international medical graduates (IMGs). IMGs are defined as physicians who have graduated from a medical school outside the United States and Canada, a population that includes US citizens and permanent...

  • Saved
CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.956464/full

BackgroundUpdated evidence was required to compare the efficacy and safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors...


Conclusions: CDK4/6 inhibitors showed better efficacy in PFS, but the benefits disappeared when taking treatment line into consideration. Specific and discrepant safety profiles were found in two categories of agents.

  • 3yr
    this very interesting and rather intriguing. In my mind patients should get either one depending on particular circumstances